Piper Jaffray maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $5.00 (from $11.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

UPDATE: RBC Capital Downgrades Orexigen Therapeutics (OREX) to Sector PerformFebruary 29, 2016 6:52 AM Notable 52-Week Highs and Lows 2/26: (ALRM) (STMP) High; (PPHM) (PMC) (HSC) LowFebruary 26, 2016 2:58 PM Unusual 11 Mid-Day Movers 2/26: (RRM) (VSLR) (SGMS) Higher; (RJET) (PPHM) (HSC) LowerFebruary 26, 2016 12:59 PM Orexigen Therapeutics (OREX) Misses Q4 EPS by 4cFebruary 26, 2016 7:03 AM Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015February 26, 2016 7:00 AM Trading Radar for 2/26: JCPenney (JCP), Foot Locker (FL), Sotheby's (BID), WP Glimcher (WPG) ReportFebruary 25, 2016 2:20 PM